TherimuneX Overview

  • Founded
  • 2005
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

TherimuneX General Information


Developer of inflammasome signaling platform designed to exploit the commercial applications of a new medical discovery. The company's platform relates to a new family of endogenous lipopeptides and their immune regulating properties leading to the development of a new therapeutic peptide, enabling doctors to treat and prevent infectious diseases including cancer and scleroderma.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 5110 Campus Drive
  • Plymouth Meeting, PA 19462
  • United States
+1 (610) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TherimuneX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Jun-2018 Completed Out of Business
3. Debt - General Completed Generating Revenue
2. Later Stage VC 01-Nov-2011 Completed Generating Revenue
1. Grant 01-Jan-2009 $636K Completed Startup
To view TherimuneX’s complete valuation and funding history, request access »